MONARCS

Monoclonal Anti-TNF: A Randomized Controlled Sepsis. A clinical trial, conducted in 157 US sites, which evaluated the efficacy of afelimomab in managing sepsis and septic shock, selecting the patients using Il-6, a cytokine marker for severity of inflammation
Results Treated patients had a 36% mortality; untreated patients, 33%

MONARCS

Immunology A clinical trial–Monoclonal Anti-TNF: a Randomized Controlled Sepsis trial which evaluated the efficacy of afelimomab in managing sepsis and septic shock, selecting the Pts using Il-6, a cytokine marker for severity of inflammation; treated Pts had a 36% mortality; untreated Pts, 33%. See Afelimomab, Sepsis.

Mentioned in ?

References in periodicals archive ?

Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial.

Treatment strategies and recommendations for Pseudomonas aeruginosa infections

72 (RAMSES study) controlled hours Severe sepsis 2634 Baseline to 72 hours secondary to documented infection (MONARCS trial) Ref.